Grail has big plans for its blood can­cer tests. The first step: Find­ing a new own­er

Last year
In Focus
Diagnostics

Genen­tech's food al­ler­gy med­ica­tion gets pri­or­i­ty re­view nod from the FDA

Last year
Pharma
FDA+

FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

Last year
R&D
Pharma

The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

Last year
Pharma

Pas­sage Bio scraps a ther­a­py; XO­MA’s new loan; Im­pel is for sale

Last year
News Briefing

Scoop: Re­silience down­sizes tech­ni­cal R&D and qual­i­ty as­sur­ance di­vi­sions

Last year
People
Manufacturing

GSK se­cures an­oth­er ex-Chi­na ADC deal with Han­soh Phar­ma with $185M up­front

Last year
Deals
China

Ex­clu­sive: Su­do Bio­sciences se­cures $116M to start tri­als of its oral and top­i­cal TYK2 can­di­dates

Last year
Financing
Startups

Ar­genx scraps pro­gram in skin au­toim­mune dis­ease af­ter Vyv­gart Hytru­lo flunks an­oth­er PhI­II tri­al

Last year
R&D

Why 2023 was the year of un­so­licit­ed ac­qui­si­tion bids — and why next year like­ly won’t be

Last year
Deals
In Focus

Aclaris halves head­count, banks on next mid-stage read­out af­ter clin­i­cal set­backs tanked shares

Last year
People

FTC lays out road map for merg­er re­view in over­haul of decade-old an­titrust frame­work

Last year
Pharma
Law

FDA ap­proves Chiesi’s gel for rare skin dis­ease af­ter ini­tial 2022 re­jec­tion for Am­ryt

Last year
Pharma
FDA+

Ger­man court de­nies va­lid­i­ty of Cure­Vac patent claim in fight with BioN­Tech over Covid-19 vac­cine 

Last year
Pharma
Law

Ver­i­ly’s chief med­ical of­fi­cer Amy Aber­nethy is step­ping down

Last year
People
Health Tech

How Eli Lil­ly is rolling out Zep­bound, the weight loss drug that can 'sell it­self’

Last year
Pharma
Marketing

Mer­ck clinch­es pri­or­i­ty re­view for pneu­mo­coc­cal vac­cine, rais­ing stakes for Pfiz­er

Last year
Pharma
FDA+

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Last year
R&D
In Focus

Pfiz­er no longer go­ing to con­duct in­ter­im analy­sis for Duchenne gene ther­a­py study by end of year

Last year
R&D

Kro­nos stops work on leukemia drug; Aldeyra shares ral­ly on eczema da­ta; Atavis­tik Bio's $40M

Last year
News Briefing

Mar­ket­ingRx roundup: Ver­tex, CRISPR get un­in­tend­ed role in SNL skit; Re­al Chem­istry and can­cer so­ci­ety de­but AI ...

Last year
Pharma
Marketing

Ex­clu­sive: Meta­bol­ic health and pri­ma­ry care start­up known­well rais­es $20M Se­ries A round

Last year
Health Tech

Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Last year
Financing
Startups

Ex­clu­sive: Kimia Ther­a­peu­tics se­cures $55M to su­per­charge co-founder’s plat­form, cre­ate ‘next-gen­er­a­tion ...

Last year
Financing
Startups
First page Previous page 227228229230231232233 Next page Last page
A service from the Financial Times